U.S. Markets close in 1 hr 46 mins

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.85+0.83 (+2.09%)
As of 2:13PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close40.02
Open40.50
Bid40.94 x 1300
Ask41.00 x 900
Day's Range40.08 - 41.20
52 Week Range12.71 - 41.26
Volume782,582
Avg. Volume1,812,147
Market Cap5.523B
Beta (5Y Monthly)1.57
PE Ratio (TTM)265.29
EPS (TTM)0.15
Earnings DateFeb 22, 2021 - Feb 26, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.55
  • Benzinga

    A Look Into Halozyme Therapeutics's Debt

    Shares of Halozyme Therapeutics (NASDAQ: HALO) moved higher by 47.48% in the past three months. Before we understand the importance of debt, let us look at how much debt Halozyme Therapeutics has.Halozyme Therapeutics's Debt Based on Halozyme Therapeutics's balance sheet as of November 2, 2020, long-term debt is at $393.63 million and current debt is at $0.00, amounting to $393.63 million in total debt. Adjusted for $65.74 million in cash-equivalents, the company's net debt is at $327.89 million.Let's define some of the terms we used in the paragraph above. Current debt is the portion of a company's debt which is due within 1 year, while long-term debt is the portion due in more than 1 year. Cash equivalents include cash and any liquid securities with maturity periods of 90 days or less. Total debt equals current debt plus long-term debt minus cash equivalents.To understand the degree of financial leverage a company has, investors look at the debt ratio. Considering Halozyme Therapeutics's $524.03 million in total assets, the debt-ratio is at 0.75. As a rule of thumb, a debt-ratio more than one indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can also imply that the company might be putting itself at risk for default, if interest rates were to increase. However, debt-ratios vary widely across different industries. A debt ratio of 40% might be higher for one industry and average for another.Why Debt Is Important Besides equity, debt is an important factor in the capital structure of a company, and contributes to its growth. Due to its lower financing cost compared to equity, it becomes an attractive option for executives trying to raise capital.However, interest-payment obligations can have an adverse impact on the cash-flow of the company. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.Looking for stocks with low debt-to-equity ratios? Check out Benzinga Pro, a market research platform which provides investors with near-instantaneous access to dozens of stock metrics - including debt-to-equity ratio. Click here to learn more. See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Highs On Wednesday * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Halozyme Raises Full Year 2020 Guidance
    PR Newswire

    Halozyme Raises Full Year 2020 Guidance

    Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc.

  • Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
    PR Newswire

    Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology

    Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE® drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressive and vision-threatening rare autoimmune disease,1 potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients.